Antibody-drug conjugates to treat gastric cancer

被引：11

作者：

Koganemaru, Shigehiro ^{[1
]}

Shitara, Kohei ^{[1
,2
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Chiba 2778577, Japan

[2] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2021年 / 21卷 / 07期

关键词：

Antibody-drug conjugate; gastric cancer; translational research; armed antibody; TRASTUZUMAB EMTANSINE; HER2-TARGETING ADC; ADVANCED BREAST; OPEN-LABEL; PRECLINICAL PROFILE; BRENTUXIMAB VEDOTIN; GENE AMPLIFICATION; ANTITUMOR-ACTIVITY; PHASE-II; CAPECITABINE;

D O I：

10.1080/14712598.2020.1802423

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction Despite new treatment options, the long-term prognosis of recurrent or inoperable gastric cancer remains poor. Antibody-drug conjugates (ADCs) are a new class of drugs and have shown promising results in clinical trials. Areas covered This review focuses on recent clinical findings and development of ADCs for gastric cancer, and summarizes the relevant resistance mechanisms or future directions of ADCs. Expert opinion Novel HER2-ADCs have led to breakthrough results forHER2(+)gastric cancer; however, several questions remain, especially in clinical settings. Translational research to elucidate ADCs' mechanisms of action or resistance will lead to more sophisticated use of ADCs and combination strategies.

引用

页码：923 / 930

页数：8